Latest Developments in Global Minimally Invasive Neurosurgical Devices Market

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Latest Developments in Global Minimally Invasive Neurosurgical Devices Market

  • Medical Devices
  • Dec 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • In April 2024, Dr. Reddy’s launched Nerivio, a drug-free, noninvasive device for migraine management. Supported by the company's M-free patient support program, this device aims to enhance the patient experience with services including onboarding, counseling, device demonstrations, doorstep delivery, flexible payment plans, educational content, and dedicated customer support.
  • In January 2023, PENTAX Medical received CE marks for its new premium video processor, the PENTAX Medical INSPIRA, and the i20c video endoscope series. This new processor is compatible with PENTAX Medical's latest endoscope models and introduces new standards for high-quality imaging.
  • In August 2023, Orthofix Medical announced the full commercial launch of their 7D Flash navigation system percutaneous module 2.0 in the U.S.. This enhanced version adds new planning features and broadens the utility of the 7D Flash neuronavigation system for minimally invasive spinal surgeries. The 7D system was originally provided by 7D Surgical, which was acquired by SeaSpine in 2021 after the merger between Orthofix and SeaSpine earlier this year.
  • In October 2022, scientists from Imperial College London successfully implanted a new bioinspired, flexible, and steerable device into the brains of living animals using a minimally invasive robotic system for the first time. This advanced platform offers high precision and less intrusive procedures and could potentially improve the detection and treatment of diseases in humans if proven safe and effective.
  • In June 2022, Boston Scientific entered into an agreement to acquire a majority stake in M.I.Tech, a South Korean manufacturer and distributor of non-vascular metal stents used for endoscopic and urologic procedures. The deal was valued at approximately USD 230 million, with Boston Scientific paying about approximately USD 11 per M.I.Tech share.

Frequently Asked Questions